Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 18, 2009

Opsona Closes $23M Financing Round

Opsona Closes $23M Financing Round

Opsona to open new facility in Switzerland

  • Opsona Therapeutics completed an €18 million, or $23 million, Series B financing round. The money will allow the firm to expand its operations into Switzerland and advance its preclinical pipeline of drug candidates targeting inflammatory diseases.

    Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital, and Seroba Kernel Life Sciences participated in the funding. Under the financing agreement, Opsona added Florent Gros, managing director at Novartis, and Manus Rogan, Ph.D., managing partner at Fountain Healthcare, to the board of directors. The company says other key appointments in the corporate and clinical areas will be announced in the coming months.

    The Dublin-based company will open a new facility in Switzerland to carry out assay development and biochemical work to expand Opsona's pipeline of immunomodulators. The company's lead product is a fully humanized mAb to a TLR, which will start clinical trials in 2010, explains Opsona.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »